ArticleClinical and molecular hepatology2014
Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B.
Article in Clinical and molecular hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Fitusiran treatment modulates the ratio between alpha- and beta-antithrombin isoforms.HemaSphere · 2026Article
- Article
- Evaluation of Transferrin Level in Iron Supplementation after Partial Hepatectomy.Bulletin of experimental biology and medicine · 2025Article
- Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China.World journal of gastroenterology · 2022Article
- Article
- Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis.Oncology letters · 2018Article
- [Research advances in nutritional assessment methods in children with chronic liver diseases].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2017Review
- Automated microfluidic platform of bead-based electrochemical immunosensor integrated with bioreactor for continual monitoring of cell secreted biomarkers.Scientific reports · 2016Article
- Proteomic profiling of HBV infected liver biopsies with different fibrotic stages.Proteome science · 2016Article
- Identification of Candidate Serum Biomarkers for Schistosoma mansoni Infected Mice Using Multiple Proteomic Platforms.PloS one · 2016Article
- Non-invasive diagnosis of liver fibrosis and cirrhosis.World journal of gastroenterology · 2015Review
- Current strategies and findings in clinically relevant post-translational modification-specific proteomics.Expert review of proteomics · 2015Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsTransferrin and alpha-1 antitrypsin are reportedly associated with liver fibrosis. We evaluated the usefulness of serum transferrin and alpha-1 antitrypsin as new liver fibrosis markers in patients with chronic hepatitis B.
methodsThe study included 293 patients with chronic hepatitis B who underwent a liver biopsy between October 2005 and June 2009, and who had no history of hepatocellular carcinoma. Serum markers and liver fibrosis stages were compared.
resultsUnivariate analysis revealed that age (P<0.001), serum platelet count (P<0.001), and serum alkaline phosphatase level (P=0.003) differed significantly between the patients with and without liver cirrhosis. Serum transferrin levels were significantly lower in advanced fibrosis than in mild fibrosis in both univariate analysis (P=0.002) and multivariate analysis (P=0.009). In addition, the serum transferrin level was significantly lower in cirrhotic patients than in noncirrhotic patients (P=0.020). However, the serum level of alpha-1 antitrypsin was not significantly associated with liver cirrhosis in patients with chronic hepatitis B.
conclusionsSerum transferrin could be promising serum marker for predicting advanced liver fibrosis in patients with chronic hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.